The mitogenic effect of 17b-estradiol (E2) on the breast is mediated by estrogen receptor alfa (ERa), hence ERa antagonists are effective in the treatment of breast cancer. The possible use of estrogen receptor beta (ERb) as a target in treatment of breast cancer is under investigation. The mouse mammary cell line HC11 expresses both ERs and was used to study the role of the two receptors in proliferation. E2 had no effect on proliferation. The ERaselective agonist 4,4 0 ,4 00 -(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol (PPT) stimulated proliferation. The ERb-selective agonist 2,3-bis(4-hydroxy-phenyl)-propionitrile (DPN) inhibited cell growth and induced apoptosis. PPT upregulated while DPN downregulated cyclin D1 and proliferating cell nuclear antigen (PCNA). Upon inhibition of ERa expression with RNA interference, E2 caused a decrease in cyclin D1 and PCNA, and increased apoptosis. When ERb expression was blocked, E2 induced proliferation and cells gained the capacity to grow in soft agar. In summary, in HC11 mammary epithelial cells, ERa drives proliferation in response to E2 while ERb is growth inhibitory. The lack of effect of E2 on HC11 cell growth is the result of the combined actions of ERa (proliferation) and ERb (apoptosis). We suggest that use of ERb agonists will be a useful addition in treatment of breast cancer, which, at present, is only aimed at inhibition of ERa. Oncogene (2005) 24, 6605-6616.
Introduction
Estrogens, acting through estrogen receptor alfa (ERa) (Greene et al., 1986) and beta (ERb) (Kuiper et al., 1996) , play a key role in mammary gland development and morphogenesis. Studies of ERa and ERb knockout mice have confirmed the importance of ERa in ductal elongation during puberty (Bocchinfuso et al., 2000) and revealed a role for ERb in differentiation of the epithelium (Forster et al., 2002) . Both receptors bind 17b-estradiol (E2) with the same affinity, but they can activate certain promoters differentially (Saville et al., 2000) and on some promoters ERb can behave as a negative modulator of ERa activity (Weihua et al., 2003; Stro¨m et al., 2004) . About 2/3 of breast tumors express ERa and 70% of these respond to the antiestrogen tamoxifen (Clarke et al., 1996) . Prolonged treatment with tamoxifen leads to resistance to the drug despite the continued presence of estrogen and progesterone receptors (Clarke et al., 1996) . At some promoters, tamoxifen is an agonist in the presence of ERb and it is possible that ERb plays an antiproliferative, proapoptotic role during tamoxifen therapy (Iwao et al., 2000a, b; Speirs et al., 2004) .
In recent years, much effort has been invested in the development of ERa-and ERb-specific agonists and antagonists. Several such compounds have been developed, and this has permitted dissection of the specific functions of each receptor. One ERa-specific agonist, 4,4 0 ,4 00 -(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol (PPT), is 410-fold more potent in binding to ERa than ERb (Stauffer et al., 2000) , whereas 2,3-bis (4-hydroxy-phenyl)-propionitrile (DPN) binds to ERb with an affinity 72-fold higher than to ERa (Meyers et al., 2001) . Both ligands induce expression of an estrogen response element (ERE)-luciferase reporter gene with potencies similar to that of E2; hence, they are considered to be ERa-and ERb-selective agonists, respectively.
In the present study, the HC11 mouse cell line was used to evaluate the effect of estrogen on mammary epithelial cells. This cell line was cloned from the COMMA-D1 cell line obtained from the mammary epithelium from a mid-pregnant BALB/c mouse (Ball et al., 1988) . These cells have stem cell-like properties such as growth factor-and hormone-dependent expression of markers for different epithelial lineages (Deugnier et al., 1999) and the ability to reconstitute partially the ductal epithelium in a cleared mammary fat pad (Humphreys and Rosen, 1997) .
The present report is a study of the roles of ERa and ERb in E2-induced proliferation. The action of each receptor was delineated with the use of ERa-and ERb-specific agonists and with ERa-and ERb-specific small inhibitory RNA (siRNA). We show that ERa mediates proliferation while ERb is proapoptotic. In addition, we found that inhibition of ERb expression can lead to cellular transformation.
Results

ERa and ERb colocalize in HC11 mammary epithelial cells
We have previously demonstrated by Western blotting that HC11 mammary epithelial cells express both ERa and ERb (Faulds et al., 2004) . In this report, we used double immunofluorescence staining to study coexpression of these receptors (Figure 1a -e). High levels of ERa surrounding the nucleus were detected in most of the cells, (panel a). ERb was also detected in most cells with higher intensity around the nucleus (panel b). Merged images are shown in panels c and e, where it is evident that although both receptors colocalize throughout the cell, ERa has a higher nuclear distribution than ERb. Both receptors were found in defined areas of the nucleus in a speckle-like pattern. The extent of staining differed between cells. At present, the reason for this is unclear but could be due to an influence from cell-cell contact and cell cycle stage on ER expression.
The staining surrounding the nucleus was studied with lamin B (red) as a marker for nuclear membrane localization (Figure 1f ) . In some cells, ERb (green) colocalized with this component of the nuclear lamina (yellow), indicating that at least ERb can be found on the inner side of the nuclear envelope. These results show that ERa and ERb colocalize in the nucleus (speckles), with a strong signal around the nuclear membrane, which in some cases may be on the inner side of the membrane and also in the cytoplasm.
Specificity of anti-ERa (MC-20) and anti-ERb (503) antibodies was evaluated on mammary glands from ERa þ / þ , ERaÀ/À and ERb þ / þ , ERbÀ/À mice, respectively (Figure 1g and h) and on ER-negative HeLa cells (not shown). A specific nuclear staining and occasional cytosolic signal along ducts was observed with MC-20 only in ERa þ / þ (panel g) but not in ERaÀ/À (panel g inset) or HeLa cells. 503 antibody gave both nuclear and cytosolic staining in ERb þ / þ (panel h) but not in ERbÀ/À mammary glands (panel h, inset) or HeLa cells.
Differential activation of ERa or ERb with selective ligands results in opposing responses in terms of proliferation and apoptosis
The effects of E2, the ERa-selective ligand PPT or the ERb-selective ligand DPN on cell proliferation were evaluated by cell counting following 48 h incubation with 1 or 10 nM of each compound (Figure 2a ). E2 did not increase proliferation, with 10 nM PPT there was a 50% increase in cell number (Po0.001) and, strikingly, with DPN, cell number decreased 25-30% (Po0.001). A combination of PPT and DPN had similar effect as E2, resulting in no change in cell number.
Expression of the proliferation associated proteins cyclin D1 and PCNA was evaluated by Western blot 24 h after exposure to 10 nM E2, PPT or DPN. Cyclin D1 expression was up-regulated by both E2 and PPT, but in DPN-treated cells its levels were lower than the control (Figure 2b ). PCNA expression also decreased following DPN treatment. No change or a slight decrease was observed with E2 and a slight increase with PPT (Figure 2c ). To further study if DPN treatment was affecting exit from G1, we evaluated the number of cells in mitosis following 6 and 24 h incubation. Mitotic index was measured as cells in mitosis/total number of cells in cultures stained with hematoxylin (10 random fields were evaluated). It was significantly higher following PPT treatment (6 h: 270.6 and 24h: 1.370.2; Po0.05); DPN decreased the number of mitoses at an early time point but no significant effect was observed after 24 h (6 h: 0.470.3; Po0.05 and 24h: 1.070.4); no significant differences were observed with E2, although there was a tendency to decreased number of mitoses at earlier time points (6 h: 0.670.3 and 24 h: 0.970.4). Ki-67 was also evaluated; only DPN caused a significant decrease after 6 h (62716 vs 91715%; Po0.01). Taken together, these results indicate that E2 and PPT have a similar effect on cyclin D1 expression while DPN plays an opposing role by transiently preventing the cells from entering the cell cycle. The lack of effect of E2 on PCNA despite induction of cyclin D1 indicates that E2 does signal cells to proliferate but that exit from G1 is inhibited. These results imply that estrogen signaling via ERa and ERb acts at different steps of the cell cycle where ERa favors entry into the cell cycle while ERb transiently inhibits it.
To further substantiate the effects of ER-selective ligands on cell proliferation, we used the MTS assay, which determines metabolic activity by reduction of tetrazolium to a colored formazan product by dehydrogenases. This is supposed to give an indirect estimation of cell proliferation. The effect of the three ligands was studied in a range of concentrations from 0.1 to 100 nM. As shown in Figure 3 , no effect was observed with E2, while a significant stimulatory response of 40-50% was obtained with both PPT and DPN (100 nM, Po0.001). With a combination of PPT plus DPN (PPT þ DPN), instead of a synergistic stimulatory effect, there was no stimulation of cell metabolism. We can speculate that ER homodimer formation is favored by binding of selective ligands and this might induce expression of different sets of genes than those induced by the ERa-ERb heterodimers. Thus, DPN increases cell metabolism but inhibits cell proliferation, whereas PPT increases both parameters. However, combined treatment with PPT and DPN, or exposure to E2, that is, simultaneous activation of ERa and ERb, results in lack of effect on either proliferation or metabolism. We can also conclude that, under our experimental conditions, the MTS assay does not reliably measure E2-induced proliferation. The negative effect on cell number observed with DPN could also be the result of an induction of apoptosis. To test this hypothesis, the number of apoptotic cells after 24 and 48 h incubation with 10 nM E2, PPT or DPN was measured with the TUNEL method ( Figure 4) . After 24 h, both E2 and DPN significantly increased apoptosis (Po0.05 and Po0.001, respectively) with highest values (four-fold increase over control) observed following DPN treatment. With E2, the increase was 2.5-fold. There was no significant increase in apoptosis after PPT treatment. Only DPN caused a significant increase in apoptosis after 48 h (Po0.001).
During involution, mammary epithelial mass is reduced by apoptosis. Bcl-2 family of proteins play an important role in this process and evidence points toward the regulation of some members of this family by sex steroid hormones (Schorr et al., 1999b) . Thus, E2-and DPN-mediated apoptosis was also studied by analysing the expression of the proapoptotic protein Bax and the E2-regulated antiapoptotic protein Bcl-x (Leung and Wang, 1999 ) between 2 and 24 h of treatment ( Figure 5 ). Bax expression was slightly higher than control throughout the whole time period studied, independently of the ligand. However, a significant increase was observed in cells treated with E2 or DPN for 24 h. The expression pattern of Bcl-x, one of the inhibitory partners to Bax, was more complex. Activation of ERb by DPN significantly decreased expression of Bcl-x at 6 h and values remained low up to 18 h, while during the same time interval, incubation with PPT tended to keep Bcl-x levels high. E2 had the same effect as PPT at 6 h while it decreased Bcl-x levels at 18 h. At 24 h after exposure to any of the ligands, Bcl-x was highly upregulated. The study of Bax and Bcl-x protein levels in HC11 cells indicates that the critical regulatory period for Bax-mediated apoptosis is between 6 and A concentration of 10 nM E2, PPT or DPN was added to the experimental medium (2% HS) and 24 or 48 h later, cells were fixed. TUNEL-fluorescein assay was performed and nuclei were counterstained with DAPI. A total of 10 random fields at Â 40 magnification were counted for TUNEL-positive cells/number of total nuclei. A representative experiment of three is shown. **Po0.05; ***Po0.001 18 h. During this time period, Bax levels increased with all of the treatments. However, the apoptosis inhibitor Bcl-x also increased in the case of PPT treatment but decreased with E2 (18 h) or DPN (6 and 18 h). These results are in agreement with the finding that gain of function of Bcl-2, another antiapoptotic protein partner to Bax, is more potent than loss of Bax function in regulating mammary epithelial cell survival in vivo (Schorr et al., 1999a) .
ERa and ERb play different roles in mammary epithelial cellular proliferation and apoptosis
The role of ERa and ERb in E2-induced cell proliferation was studied with RNA interference (RNAi) to block alternatively ERa (siERa) or ERb (siERb). The specificity and efficiency of each siRNA were tested in transient transfection experiments in HC11 cells together with YFP-mERa or GFP-mERb expression vectors. Figure 6a shows that siERa and siERb decreased ERa and ERb expression, respectively, while the control siRNAs with a point mutation (mutsiERa and mutsiERb) or the mock vector had no effect. Later, stably transfected HC11 cell lines (HC11-siERa, HC11-siERb or HC11-mock) were obtained and the efficiency of each siRNA was evaluated by Western blot of wholecell extracts (Figure 6b ). The left panel shows the specificity of anti-ERa (MC-20) or anti-ERb (14C8) antibodies. Neither ERa nor ERb was detected in NIH-3T3 or HeLa cell extracts. A 67 kDa band corresponding to ERa was observed in T47-D and HC11 cells. A band of 58-60 kDa corresponding to ERb was observed in T47-D cells. Results from stably transfected cell lines are shown in the right panel. ERa expression was lower in HC11-siERa compared to HC11 or HC11-mock cells, while ERb expression was lower in HC11-siERb compared to HC11 or HC11-mock cells.
Cell proliferation was evaluated on HC11 control and siRNA stably transfected cells treated with 10 nM E2 (Figure 7a, left panel) . Inhibition of ERa expression (HC11-siERa) had a negative effect on cell number. That is, when E2 was bound to ERb, cell number decreased by about 30% (Figure 7a , left panel; Po0.05). On the contrary, E2 increased cell number by 50% (Po0.05) in HC11-siERb. No differences between the control HC11 and HC11-mock cells were observed. To rule out the possibility of artifacts due to siRNA expression per se, mutsiERa and mutsiERb were transiently transfected into HC11 cells. Following this, cells were treated with 10 nM E2 and counted 48 h later ( Figure 7a , right panel). Similar results as those with stably transfected cells were obtained in HC11 cells transiently transfected with siERa or siERb but no effect was evident with the mutated siRNAs. These observations support the idea that stimulation of the ERb pathway decreases cell number, while the opposite is observed when ERa is activated.
Cyclin D1 and PCNA expression was evaluated by Western blot of whole-cell extracts from each stable cell line, following 24 h treatment with 10 nM E2 ( Figure 7b ). As previously shown, an increase of cyclin D1 levels was observed after E2 incubation in HC11 or HC11-mock cells (in accordance with Figure 2b ). In HC11-siERa cells, E2 downregulated cyclin D1 expression (Figure 7b) . Surprisingly, in E2-treated HC11-siERb cells, cyclin D1 was not upregulated. Expression of PCNA was slightly downregulated in HC11 or mocktransfected cells, and HC11-siERa cells. PCNA was not downregulated in HC11-siERb (Figure 7b ). These observations are consistent with the fact that E2 acting through ERb (HC11-siERa cells) inhibits proliferation.
The effect of siERa and siERb on apoptosis of E2-treated HC11 cells was evaluated with TUNEL assay (Figure 7c ). Apoptosis index did not vary between untreated wild-type HC11 cells and the stable cell lines (not shown). Conversely, following 48 h incubation with E2, a significant (Po0.001) increase was observed in HC11-siERa cells and lower levels in HC11-siERb cells compared to the untreated control.
Decreased ERb expression favors epithelial transformation
Impaired regulation of proliferation/apoptosis pathways is one factor influencing cell transformation. Consequently, effect of loss of ERb expression on HC11 cell transformation was investigated. Figure 8a shows a representative picture of growth in soft agar, where anchorage-independent growth was evident in HC11-siERb cells (arrows) but not in HC11, HC11-siERa or mock-transfected cells (only HC11 is shown for comparison). In the case of HC11-siERb cells, a significant increase in the percentage of colonies was observed following 15 days treatment with 10 nM E2 (Figure 8b , Figure 5 Expression of Bcl-2 family members. After 2, 6, 18 and 24 h treatment with 10 nM E2, PPT or DPN, western blots of whole-cell extracts were developed with anti-Bax or Bcl-x antibodies. The intensity of the bands was normalized to that of b-actin in the same sample. Normalized values were compared to the untreated control, arbitrarily set to 1. *Po0.01
Po0.05). Treatment with 10 nM E2 together with 10 nM 4OH-tamoxifen (Tam) or ICI 182 780 (ICI) partially inhibited colony formation by HC11-siERb cells (Figure 8b ). No effect was observed after antiestrogen treatment of wild-type HC11 or the other stable cell lines (not shown). The effect of 10 nM E2 on the number of cells per colony was also studied in HC11-siERb cells. The most frequent value observed in 75% of the colonies in the untreated group was six cells per colony (maximum ¼ 14) while E2 increased the cell number to 11.5 (maximum ¼ 20). When cells were treated with a combination of 10 nM E2 and 10 nM Tam or ICI, the number of cells decreased to 5.5 (maximum ¼ 8) and 7.5 (maximum ¼ 11), respectively. Thus, E2 exerted a significant tendency to increase the number of cells in each colony, which was blocked by Tam or ICI (ao0.05), suggesting that these effects are ER mediated. The results shown here indicate that an imbalance between ERa and ERb expression due to reduced ERb levels can lead to cell transformation.
Discussion
The mouse mammary cell line, HC11, is known to express both ERa and ERb (Faulds et al., 2004) and reflects the situation in the late pregnant and lactating states, where the mammary glands are resistant to the proliferative effects of estrogen (Shyamala and Ferenczy, 1982) , but express both receptors. The mechanisms responsible for resistance to E2-induced proliferation are not known but there have been suggestions of reduction in coactivators and increase in corepressors. In this study, we show that both ERa and ERb are functional and can be activated in HC11 cells. The reason for resistance to E2-induced proliferation is the We found that ERa and ERb are expressed by all HC11 cells and colocalize in the nucleus and perinuclear region. Despite this, HC11 cell growth was neither stimulated nor inhibited by E2 at concentrations ranging from 0.1 to 100 nM. The ERa-selective ligand PPT (Stauffer et al., 2000) and the ERb-selective ligand DPN (Meyers et al., 2001) , which, based on reporter assays, were both considered to be agonists with a similar potency to that of E2, were used to study the effects exerted by one or the other receptor. Upon exposure of the cells to PPT, there was an increase in cell number of nearly 50% while DPN caused a decrease of 30% compared to the untreated cells. These results indicate that activation of ERb leads to inhibition of proliferation and increase in apoptosis. Both selective ligands had positive effects on cell metabolism measured as dehydrogenase activity. Activation of ERa independently of ERb, and vice versa, increased cell metabolism, but activation of both receptors simultaneously (E2 or PPT þ DPN) had no effect. One hypothesis in line with the idea of selective estrogen receptor modulators (SERMs), is that -depending on the type of liganddifferent sets of coactivator/corepressor proteins will be recruited to the transcription complexes, resulting in transcription of different genes depending on the type of ER dimer-coregulator complex formed. In fact, ligands such as estrone and genistein induce SRC-1 recruitment to ERb with much higher efficiency compared to ERa (Margeat et al., 2003) and selective ligands such as PPT show some quantitative differences in their ability to recruit members of the SRC/p160 family (Kraichely et al., 2000) . In addition, our results show that the MTS assay cannot be used to measure accurately estrogenic regulation of cell proliferation.
ERa and ERb activate transcription from consensus and nonconsensus ERE reporter genes and it has previously been shown that the transactivation potency of the two receptors differs at different EREs (Hall and Korach, 2002) and that this potency is greatly influenced by the structure of the ligand. The proliferative effects of E2 are mediated not only by transcriptional activation Mean7s.e. of three independent experiments is shown. The right panel shows, HC11 cells transiently transfected with siERa, siERb and the control mutated sequences (mutsiERa and mutsiERb). Following 48 h in the presence of E2, cells were counted, normalized to firefly luciferase activity and, for each transfection, values were related to the untreated group. Mean7s.e. of two independent experiments carried out in sextuplicate is shown. Differences between treatments and control were analysed using Student's t-test. **Po0.05; ***Po0.001. (b) Cyclin D1 and PCNA expression in siERa or siERb stably transfected HC11 cell lines after 24 h incubation with 10 nM E2. b-Actin was used as loading control. Blots are representative of three experiments. (c) TUNEL-assay following 48 h incubation with 10 nM E2. TUNEL positive cells/total number of cells in 10 random fields at Â 40 magnification were counted; apoptosis index was calculated comparing to each untreated cell line. **Po0.05; ***Po0.001. The experiment is a representative of two from ERE promoters but also by the interaction of ERs with AP-1 sites via protein-protein interactions of ER with AP-1 binding proteins like jun and fos (Kushner et al., 2000) . The two receptors can have opposing activities on AP-1-driven promoters, such as the cyclin D1 promoter (Liu et al., 2002) where ERa is an activator while ERb is repressive. Our results with HC11 cells indicate that the opposing activities of ERa and ERb on AP-1 sites are responsible for the resistance to E2-induced proliferation. As reported in human breast cancer cell lines (Frasor et al., 2003) , E2 and PPT increased cyclin D1 expression in HC11 cells while DPN reduced the level of cyclin D1. Interestingly, PCNA expression as well as mitotic index was increased only with PPT treatment but not with E2, and a decrease of these parameters was observed with DPN. These results suggest a stimulation of cyclin D1 promoter by ERa and a block in G1 downstream of cyclin D1 by ERb.
Treatment of HC11 cells with 10 nM E2 during 24-48 h influenced both proliferation and apoptosis. There was increased cyclin D1 expression, as well as increased apoptosis. With TUNEL assay, it was clear that DPN induced apoptosis while PPT did not. We conclude from these data that there are two E2-activated pathways, that is, proliferation (ERa) and apoptosis (ERb), and activation of both pathways by E2 is responsible for the lack of effect on cell number.
Throughout postlactation involution of the mammary gland, apoptosis is strongly regulated by expression of Bcl-2 family proteins (Schorr et al., 1999a, b) . In our study, the role of two members of this family was investigated. At 18 and 24 h, the proapoptotic protein Bax was upregulated by E2 and DPN. However, the antiapoptotic protein Bcl-x was downregulated between 6 and 18 h by DPN and not by PPT. Thus, in the first 24 h after administration of ligands, apoptosis prevails in DPN-treated cells. Apoptosis remained high in DPNtreated cells 48 h after treatment although Bax and Bcl-x remained high. The reason for sustained apoptosis despite increase in Bcl-x has not been investigated, but it is possible that at these later time points other members of the Bcl-2 family may have become important players, or that the initial downregulation of Bcl-x is enough to start the apoptosis process. In the normal mouse mammary gland, 48 h after involution, both Bax and Bcl-x mRNA were higher than during lactation (Schorr et al., 1999b) . The antiapoptotic protein Bcl-2 is an E2-induced gene (Zhang et al., 1999) . Its presence in breast cancer is highly correlated with ER expression and favorable prognosis (Gasparini et al., 1995; Elledge et al., 1997) . This is in agreement with the inhibitory effect of the ER antagonist tamoxifen on Bcl-2 expression (Zhang et al., 1999) as shown in the MCF-7 cell line. Bcl-2 has been shown to be an ERb-repressed gene in the ventral prostate (Imamov et al., 2004) ; so it is possible that the effect of tamoxifen could be due to its action as an ERb agonist at AP-1-regulated promoters (Kushner et al., 2000) .
Blocking ERa or ERb expression with siRNAs confirmed what was found with ERa-or ERb-specific ligands. Inhibition of ERa expression in HC11-siERa cells decreased proliferation in an E2-dependent way, while blocking ERb expression in HC11-siERb cells caused an increase in cell number. These results imply that, in a nonmalignant cell line, the ratio of ERa to ERb in cells determines whether or not E2 will induce proliferation. On the other hand, the inhibitory response achieved by E2 in HC11-siERa cells was not only due to decreased proliferation but also due to, as a consequence of reduced ERa levels, E2 binding to ERb and activation of apoptosis, as was as seen with the selective ERb ligand DPN.
To date, there is no consensus on the role of ERb in breast cancer (Fuqua et al., 2003) . One study shows that ERa mRNA is upregulated in ER positive breast cancers while ERb is downregulated (Iwao et al., 2000a, b) . Other studies, using RT-PCR, have shown that ERb was expressed at much lower rates than ERa (Dotzlaw et al., 1997; Speirs et al., 1999) . Shaaban et al. analysed ERa and ERb protein expression in 53 normal breasts and compared the results with those from a cohort of histologically distinct breast lesions of different prognostic risk (Shaaban et al., 2003) . The authors suggested that the tissue concentration, relative occurrence and/or interaction of these two types of ERs may play an important role in modulating mammary tumorigenesis.
The results reported in this study, in which E2 acting through ERb has a negative effect on epithelial cell growth, are in accordance with findings by Omoto et al. (2003) in MCF-7 cells and Stro¨m et al. (2004) , who recently showed that overexpression of ERb in T47-D cells reduces cell proliferation with a concomitant decrease of many regulatory components of the cell cycle. The inhibitory effects of E2 have also been reported by Lanari's group in a well-established mouse mammary cancer model. These tumors of ductal histological type express high levels of estrogen and progesterone receptors (Molinolo et al., 1987) and regress with E2 treatment administered subcutaneously due to an increase in apoptosis and the cell cycle inhibitory proteins p21waf, p27 and p53 (Vanzulli et al., 2002) . Growth inhibition in response to E2 was also observed in primary cultures established from these tumors (Lamb et al., 2003) . The inhibitory effects of E2 are in line with the observation that DPN induces apoptosis in HC11 cells.
HC11 cells do not form tumors when transplanted syngeneically, in fact they have the ability to repopulate partially a cleared mammary fat pad giving origin to normal ductal structures. However, when ERb expression was blocked, HC11-siERb cells were able to form colonies in soft agar, indicating that HC11 cells were transformed. This result could be explained by the findings of Fo¨rster et al. on mammary glands from pregnant ERb knockout mice where decreased levels of adhesion molecules such as E-cadherin, connexin 32, occludin and integrin a2 as well as altered tight junctions (Forster et al., 2002) , indicative of a less differentiated phenotype, were observed. Studies in MCF-7 breast cancer cell lines transfected with ERb showed a decrease in the number of colonies growing in soft agar (Omoto et al., 2003) . Interestingly, during carcinogenesis, the relative ratio of ERa/ERb expression was also reported to increase (Leygue et al., 1998) .
There are few nonmalignant cell lines reported that express both ERs. This makes the HC11 cell line a good model for studies on the interplay between ERa and ERb in epithelial growth. In this study, we focused on the proliferation response to E2 and found that the 'yinyang' relationship between both ERs not only prevails at the promoter level as reported earlier for cyclin D1. Estrogen also simultaneously activates different signaling pathways that, probably depending on ERa and ERb levels, modulate the normal epithelial response to E2, which may be altered at some stage of breast cancer development.
Materials and methods
Hormones, reagents and antibodies
RPMI 1640 medium without phenol red, L-glutamine, trypsin-EDTA and gentamycin were from Gibco, BRL. Epidermal growth factor (EGF), insulin, E2, DAPI, diaminobenzidine (DAB) and gelded horse serum (HS) were from Sigma. Fetal bovine serum (FBS) was from Integro (Dieren, Holland). PPT was kindly provided by KaroBio, Sweden and DPN was from Tocris. The primary antibodies used were rabbit anti-mouse ERa (MC-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), the noncommercial chicken anti-human ERb (503) antibody developed in our own laboratory, anti-human lamin B (Santa Cruz), rabbit anti-human cyclin D1 (H-295, Santa Cruz), mouse anti-human PCNA (PC-10, Santa Cruz), rabbit anti-human Bax (Upstate Biotechnology), rabbit anti-human Bcl-x (B22630, Transduction Labs), mouse anti-human ERb (14C8, GeneTex) and anti-mouse b-actin antibody (ab8227, GeneTex). The secondary antibodies were goat anti-rabbit-TRITC (Sigma) or anti-chicken-FITC (Zymed).
Cell culture HC11 cells were grown and maintained in complete medium (RPMI 1640, L-glutamine, 50 mg/ml gentamycin, 10% FBS, 10 ng/ml EGF and 5 mg/ml insulin). After 24 h attachment, the medium was changed for experimental medium (2% HS, 5 mg/ ml insulin and L-glutamine) with or without the addition of E2, PPT or DPN.
Note on the use of HS: Preliminary experiments indicated that 2% steroid stripped FBS (ssFBS) was not a good choice of medium to study proliferation in HC11 cells. The cells did not grow well under these conditions and the results were not reproducible. Cell number was 3875% (n ¼ 3) lower with 2% ssFBS compared to 2% HS; cell metabolism was 6474% (n ¼ 4) lower. On the other hand, metabolic rate was 2872% (n ¼ 4) lower with 2% HS compared to the same concentration of normal FBS. Based on the fact that results with HS were reproducible and that E2 levels in HS are lower than in FBS (8 pM E2 in HS vs 134 pM in FBS) (Visser-Wisselaar et al., 1997) , we decided to use 2% HS in order to have a good window to see stimulatory effects.
Immunofluorescence
Cells were grown on glass microscope coverslides. At 70% confluence experimental medium was added. 24 h later, the cells were fixed in 10% buffered formalin and antigen was retrieved in 10 mM citrate buffer, pH 6.5, for 10 min. Cells were permeabilized with 0.5% Triton X-100 and unspecific binding was blocked with 10% HS in 0.1% Tween 20-PBS. After incubation with the antibodies, the slides were mounted in anti-fading medium (Vectashield Hardset medium, Vector Labs) and visualized in a Leica confocal microscope.
Immunohistochemistry
Paraffin-embedded tissues were hydrated through decreasing ethanol washes, stained with the indicated primary antibodies and the signal visualized with biotin-streptavidin-peroxidase method (ABC, Vector) and DAB substrate. In selected experiments, cells were grown on coverslides to 70% confluence, treated with 10 nM E2, PPT or DPN for 6 and 24 h and stained with Ki-67 antibody (Dako). Number of Ki-67 positive nuclei/total nuclei was counted in 10 random fields at Â 20 magnification. Sections were counterstained with hematoxylin.
Cell counting
A total of 10 000 cells were seeded in 24-well plates in complete medium. 24 h later, the medium was replaced by experimental medium with or without hormone addition and, after 48 h, cells were detached and counted in a Bu¨rker chamber. The experiments were conducted in sextuplicate. Proliferation index was calculated comparing to the untreated control within the same experiment, which was arbitrarily set to 1. Except where indicated, the mean7s.e. of at least four experiments is shown.
MTS assay
A total of 1000 cells were seeded in complete medium on 96-well plates. After 24 h, the hormones were added in experimental medium. The cells were treated for 48 h with one medium change every 24 h and cell metabolism was measured with the MTS reagent (Promega, Madison, WI, USA) according to the manufacturer's instructions. Reduction of the MTS tetrazolium compound was measured at 490 nm using a Spectramax 250 spectrophotometer (Molecular Devices Corporation). The experiments were conducted in octuplicate. The proliferation index was calculated for each treatment comparing to the untreated control within the same experiment, which was arbitrarily set to 1. The mean7s.e. of at least six experiments is shown.
TUNEL assay
Cells were grown on glass microscopy coverslides. At 70% confluence, they were treated with 10 nM E2, PPT or DPN in experimental medium. After 24 or 48 h, the cells were fixed in 10% buffered formalin. TUNEL assay was performed according to the manufacturer's protocol (Roche Diagnostics, Sweden). Apoptosis index was quantified by counting the number of apoptotic nuclei/number of total nuclei stained with DAPI; 10 random fields at Â 40 magnification, with approximately 30-40 cells, were counted for each treatment. Apoptosis index was calculated comparing to the control arbitrarily set to 1. Unless stated otherwise, the mean7s.d. of an experiment representative of three is shown.
Whole-cell extracts
Cells were washed with ice-cold PBS, spun in a microcentrifuge and resuspended in lysis buffer (1% NP-40, 50 mM Tris-HCl, pH 7.5, 140 mM NaCl, 2 mM EDTA, 10 mg/ml leupeptin, 10 mg/ ml pepstatin, 0.2 U/ml aprotinin, 1 mM PMSF and 1 mM Na 3 VO 4 ). The lysate was incubated for 20 min on ice and centrifuged at 20 000 g for 20 min at 41C. Protein quantification was performed using Bradford reagent (BioRad).
Western blotting
Whole-cell extracts (75 mg of protein) were resolved on 10 or 12% SDS-PAGE and transferred onto a PVDF membrane by semidry blotting. The membranes were blocked with 5% (w/v) milk protein dissolved in PBS and incubated overnight at 41C with the indicated primary antibodies. The secondary antibodies were coupled to horseradish peroxidase (Sigma). The luminescent signal was detected with the enhanced chemiluminescence kit (ECL, Amersham). Band intensity was quantified with Density One software (BioRad). Differences were calculated first by normalizing the intensity of each band to that of b-actin in the same sample; thus, intensity variations will be independent of loading efficiency. Second, fold difference was calculated setting the untreated (normalized) control to 1. Experiments were repeated at least times times and mean7s.d. is shown in bar graphs.
Construction of siRNAs
pSUPER (Oligoengine, Seattle, WA, USA) was used to express the siRNAs. The sequences were chosen with 'siRNA Selection Program' (Whitehead Institute for Biomedical Research, 2003) . The custom-designed oligos were from DNA Technology A/S, Denmark. The sequence to block ERa (siERa) was 5 0 -GCTCCTGTTTGCTCCTAAC-3 0 (homologous to bp 1395-1417 of the mouse ERa cDNA) and to block ERb (siERb) was 5 0 -GTGCCAGCGAG CAGGTGCA-3 0 (homologous to bp 472-494 of the mouse ERb cDNA). The specificity of these oligos was controlled by inserting a point mutation in base 9 (T for G in mutsiERa and G for T in mutsiERb). Generation of the plasmids was carried out following the manufacturer's suggestions (oligoengine. com).
Transient transfections
HC11 cells were grown in complete medium until 50% confluence, and then transfection was performed with Fugene (Roche). A double transient transfection was carried out to control the blockade efficiency of each siRNA: 1 mg pCMX-YFP-mERa (YFP-mERa) with 0.5 mg siERa or mutsiERa; alternatively the same amounts of pCMX-GFP-mERb (GFP-mERb) with siERb or mutsiERb. The cells were grown for 24 h, fixed in 10% buffered formalin and differences between YFP or GFP intensity were evaluated by observation of random fields under the same microscope settings. To control the specificity of siRNAs in the response to E2 in cell counting experiments, cotransfection of 0.5 mg of each pSUPER-siRNA plasmid together with 100 ng of pGL3-control vector coding the firefly luciferase gene (Promega) was performed. Cells were simultaneously transfected and treated with or without 10 nM E2. After 2 days, cells were counted and number of cells/ml was normalized to luciferase activity in each well. Two independent experiments were carried out, each comprising sextuplicates for each treatment. Following normalization, proliferation index was calculated comparing to the untreated control within the same experiment, which was arbitrarily set to 1. The mean7s.e. of two experiments is shown.
Stable transfections
HC11 cells were cotransfected with 10 mg of the described pSUPER-siRNA vectors and the same amount of pEF6/V5-HisC (Invitrogen, with blasticidin resistance). The transfection method was calcium phosphate precipitation as described previously (Petersen and Haldosen, 1998) . Cells were routinely maintained in complete medium plus blasticidin S (15 mg/ml; Invitrogen). The experiments were performed in the absence of selection antibiotic.
Growth in soft agar
Six-well plates were prepared by adding a 2 ml bottom layer of 1.3% noble agar dissolved in RPMI 1640 medium. After solidification, 0.7% noble agar was diluted in experimental medium and 1 Â 10 5 cells were added when the temperature reached 401C. The mix was poured on top of the bottom layer. Next, 200 ml of experimental medium with or without 10 nM E2 was added and replaced every 2 days. The cultures were grown in a humidified chamber at 371C with 5% CO 2 . Anchorageindependent growth was quantified after 15 days by counting number of colonies with more than four cells and number of cells/colony in 10 random fields at Â 10 magnification. Experiments were performed in duplicate and two independent experiments were carried out.
Statistical analysis
Results from treatment with E2, PPT and DPN (comparing to untreated controls) were analysed with one-way ANOVA and Tukey's multiple post test. The experiments with siRNAtransfected cells, where the effects of E2 on each cell line were compared to untreated controls, were analysed with Student's t-test. Statistical significance of differences between number of colonies grown in soft agar was evaluated by one-way ANOVA and Tukey's multiple post test; differences between number of cells/colony were analyzed by w 2 test for trend with a 95% confidence interval.
Abbreviations
ERa, estrogen receptor alfa; ERb, estrogen receptor beta; E2, 17b-estradiol; PPT, 4,4 0 ,4 00 -(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol; DPN, 2,3-bis(4-hydroxy-phenyl)-propionitrile; ERE, estrogen response element; HS, horse serum; PCNA, proliferating cell nuclear antigen; RNAi, RNA interference; siRNAs, small inhibitory RNAs; SERMs, selective estrogen receptor modulators.
